EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes

Mona Arabzadeh, Yi-Han Tang, Christelle Colin-Leitzinger, Sadegh Marzban, Daniel Walgenbach, Stefania Morganti, Vaidhyanathan Mahaganapathy, Erika Harper, Mingxiang Teng, Jacob K Kresovich, Iman Washington, Heather A Parsons und 5 weitere

Journal of Clinical Investigation · 15.07.2026 · 136 (14)

DOI: 10.1172/jci204429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 09.06.2026. Verfasst von Mona Arabzadeh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems and Computational Biology, and. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Breast Neoplasms, Mutation, Hematopoietic Stem Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health and the National Cancer Institute, H. Lee Moffitt Cancer Center & Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without hematologic abnormalities. In patients with solid tumors, CH is associated with higher mortality and may evolve to therapy-related myeloid neoplasms; however, the mechanisms by which cancer treatments promote CH dynamics remain largely unknown. Here, we analyzed 392 serial samples from a prospective cohort of patients with breast cancer and show that cytotoxic treatments led to strong therapeutic bottlenecks, resulting in significant reductions in hematopoietic allelic populations and differential clonal selection. Positively selected CH that expanded through dose-dependent therapeutic bottlenecks harbored mutations in TP53 , PPM1D , SRCAP , DNMT3A , and YLPM1 . Patients with positively selected CH during treatment had the shortest progression-free and overall survival compared with patients with unchanging or negatively selected CH across all therapies. These findings, validated in independent breast cancer and pan-cancer cohorts, provide strong evidence for the clinical relevance of monitoring CH during cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clonal HematopoiesisBreast NeoplasmsMutationHematopoietic Stem CellsNeoplasm ProteinsHumansFemale

Stichwörter der Autor:innen

Breast cancerClinical ResearchClonal selectionGeneticsHematopoietic stem cellsOncology

Substanzen

Neoplasm Proteins

Autor:innen und Institutionen

  • Center for Systems and Computational Biology, and.
  • Center for Biomedical Informatics, Bioinformatics Department, Rutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey, USA.
  • Department of Cancer Epidemiology.
  • Department of Biostatistics and Bioinformatics, and.
  • Department of Integrated Mathematical Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Department of Internal Medicine, University of South Florida, Tampa, Florida, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health and the National Cancer Institute
  • H. Lee Moffitt Cancer Center & Research Institute
  • Rutgers Cancer Institute Biomedical Informatics Shared Resource
  • New Jersey Commission on Cancer Research

Zitieren

APA

Arabzadeh, M., Tang, Y. H., Colin-Leitzinger, C., Marzban, S., Walgenbach, D., Morganti, S., Mahaganapathy, V., Harper, E., Teng, M., Kresovich, J. K., Washington, I., Parsons, H. A., Garber, J. E., West, J., Ganesan, S., Khiabanian, H., & Gillis, N. (2026). Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes. Journal of Clinical Investigation, 136(14). https://doi.org/10.1172/jci204429

Vancouver

Arabzadeh M, Tang YH, Colin-Leitzinger C, Marzban S, Walgenbach D, Morganti S, et al. Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes. Journal of Clinical Investigation. 2026;136(14). doi:10.1172/jci204429

BibTeX
@article{Arabzadeh2026,
  author = {Arabzadeh, Mona and Tang, Yi-Han and Colin-Leitzinger, Christelle and Marzban, Sadegh and Walgenbach, Daniel and Morganti, Stefania and Mahaganapathy, Vaidhyanathan and Harper, Erika and Teng, Mingxiang and Kresovich, Jacob K and Washington, Iman and Parsons, Heather A and Garber, Judy E and West, Jeffrey and Ganesan, Shridar and Khiabanian, Hossein and Gillis, Nancy},
  title = {Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {14},
  doi = {10.1172/jci204429}
}
Kostenlos starten →